| Dallas Podiatry Works | |
|
12221 Merit Dr Ste 280, Dallas, TX 75251-2242 | |
| (972) 853-7100 | |
| (214) 774-4955 |
| Full Name | Dallas Podiatry Works |
|---|---|
| Type | Facility |
| Speciality | Durable Medical Equipment & Medical Supplies |
| Location | 12221 Merit Dr Ste 280, Dallas, Texas |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124651872 | NPI | - | NPPES |
| 7736730041 | Other | NSC DME SUPPLIER |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213E00000X | Podiatrist | (* (Not Available)) | Secondary |
| 332B00000X | Durable Medical Equipment & Medical Supplies | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dallas Podiatry Works 8135 Forest Ln # 515057, Dallas, TX 75230-2472 Ph: (469) 850-5760 | Dallas Podiatry Works 12221 Merit Dr Ste 280, Dallas, TX 75251-2242 Ph: (972) 853-7100 |
News Archive
A new study examining whether patients with chronic Hepatitis C virus (HCV) were routinely vaccinated against Hepatitis A virus (HAV) found that vaccination rates were low, even though HAV vaccination is recommended for patients with chronic liver disease.
Learn From Apps, co-founded by Rahul Gosain, M.D. and Rohit Gosain, M.D. continues to see success with their unique Question of the Day app for medical students that helps them prepare for their United States Medical Licensing Examination.
A single change in a protein may play a role in whether someone develops Parkinson's disease, say University of Florida Genetics Institute researchers writing in a recent issue of the Proceedings of the National Academy of Sciences.
Researchers from four leading cancer centers have confirmed that an analysis involving a panel of genes can be used to predict which lung cancer patients will have the worst survival. The finding could one day lead to a test that would help determine who needs more aggressive treatment.
Daiichi Sankyo Company, Limited and ArQule, Inc. today announced that the first patient has been enrolled in the Phase 3 trial of ARQ 197, an investigational selective inhibitor of the c-Met receptor tyrosine kinase, in combination with erlotinib, for patients diagnosed with non-squamous, non-small cell lung cancer (NSCLC) who have received one or two prior systemic anti-cancer therapies.
› Verified 8 days ago